Regenxbio (NASDAQ: RGNX), the development partner for AbbVie’s (NYSE: ABBV) gene therapy ABBV-RGX-314, has announced results from a Phase I/IIa trial focused on wet age-related macular degeneration (wAMD). This announcement complements the preliminary results shared earlier in the year.
The 2-year data from the trial indicate that a single administration of the potential first-in-class gene therapy has led to stable or improved visual acuity and retinal anatomy in patients with wAMD. Moreover, interim results from a 4-year follow-up study demonstrate that the treatment is well-tolerated over the long term.
The complete dataset is anticipated to be submitted to regulatory authorities for review between 2025 and 2026, marking a significant milestone in the development of this novel therapeutic approach for wAMD.- Flcube.com
